Celerion

We have become aware of an individual who is falsely representing themselves as a member of the Celerion HR team. Please be cautious when responding to any communication that purports to come from Celerion. All email communication from Celerion will come from an email address appended @celerion.com. No other addresses are legitimate. #hr

Once a study is awarded, we can be ready in a matter of weeks to start participant dosing. We built efficiencies into our start-up processes, have the capacity to conduct multiple ADME studies at once and have the expertise to execute them. Our dedicated team of ADME specialists, including our on-site Nuclear Pharmacist, have conducted more than 100 radiolabeled clinical studies. Read more: https://lnkd.in/e8Hk8bdE #ADMEExperts #ClinicalStudies #MultiStudyCapacity #ClinicalInnovation

LC-MS/MS is a mature technology in Bioanalysis and is often called a commodity. This may be true as it is available in many laboratories around the world. However, with today’s complex new modalities, highly challenging small molecules, peptides, and oligonucleotides, the challenges in developing LC-MS/MS assays are greater than ever. At Celerion, we’ve been doing LC-MS/MS analysis in our laboratories since 1992. We have a long history of innovations and experience with challenging projects. For instance, we have performed bioanalysis of peptides and oligonucleotides for over 20 years. The complex small molecules such as protein degraders and biomarkers often require close collaboration with our on-site clinics for proper sample collection or our LBA and Flow Cytometry teams for associated biomarker analysis. In the case of ADC’s you get all of your complex bioanalysis under one roof with one set of management. Even the traditional small molecules are smaller, stickier, less stable, and nonpolar. All challenges that a lab with experience must address. Learn more about Celerion's Bioanalytical Services: https://lnkd.in/e94Jchx #Bioanalysis #LCMSMS #Peptides #Oligonucleotides #SmallMolecules #DrugDevelopment #PharmaResearch

Our multidisciplinary team of Regulatory, Clinical Pharmacology, and CMC experts work to identify potential deficiencies in submission packages and suggest potential solutions to strengthen your drug application. Learn more: https://lnkd.in/e-sCYGCk #RegulatoryAffairs #GapAnalysis #ClinicalPharmacology

Respiratory and nasal challenge tests in a clinical trial can expedite drug development by demonstrating target engagement and efficacy prior to patient exposure in a relatively small study in a well-controlled environment. In addition, bioavailability assessment during a nasal allergen assessment is essential for drugs intranasally administered. Learn about the merits and limitations of various respiratory and nasal challenge tests: https://lnkd.in/eXNC4pAC https://lnkd.in/gGJbzGP #RespiratoryChallenge #AllergenChallenge #RespiratoryCenterOfExcellence #BelfastClinic

Celerion has been called the most automated bioanalytical laboratory in the industry. Our approach is the strategic incorporation and use of bioanalytical laboratory automation to achieve controlled and error-free assays with improved accuracy, efficiency, and throughput. Our bioanalytical laboratories are market leaders in the implementation of automation with over 25 automation instruments, including Hamilton Stars, Tecan EVOs, and Caliper SciClone G3s. There are many reasons we perform automation in bioanalytical laboratories, including: - Enhanced consistency - Quality improvement - Higher sample throughput? - Real-time sample verification - Increased versatility in the workforce - Improve efficient and effective use of labor resources Learn more: https://lnkd.in/eunva39X ? https://lnkd.in/eTzWgDwz #Bioanalytical #BiotechInnovation #AutomatedLabs #LabEfficiency #ResearchExcellence

Discover how Celerion’s expertise drives success in renal and hepatic insufficiency studies. Hear from Abbey Townsend, our Senior Director of Global Clinical Development, as she breaks down key challenges and strategies for managing PK studies efficiently and cost-effectively. Watch now to see how our partnerships with top investigators help navigate these complex trials! https://lnkd.in/ewctji5m Contact us to learn how we can support your next drug development program: https://lnkd.in/eznFHuwS #ClinicalResearch #RenalStudies #HepaticStudies #Pharmacokinetics #CRO

Our Protocol Scientists tailor your study design to get the most out of your trial with effective and efficient solutions for DDI studies Learn more: https://lnkd.in/eUzpEvqm #DrugInteractions #ProtocolWriting

Celerion is heading to Barcelona for the 17th Annual EBF Open Symposium, November 20-22! We’re excited to connect with the bioanalytical community and share insights on key advancements in the field. Stop by Booth #2B to meet our experts and discuss the future of bioanalysis. While you're there, enjoy a refreshing smoothie! Join us for two informative speaking presentations: November 21 at 5:40 - 6:00 Singlicate Biomarker Assay: Enhancing Assay Performance by Surrogate Matrix Optimization November 22 at 9:00 - 9:20 The Rollercoaster Between Free Drug Tolerance and Target Interference in the Development of an Antidrug Antibody Assay Presented by Lysie Champion And don’t miss our posters: 1. Maximizing Throughput in Automated Biomarker Assays 2. Low Cut Points: Where Has Our Biological Variability Gone? – by Lysie Champion Learn more about EBF Open Symposium: https://lnkd.in/e6H9PW6U #EBFOpenSymposium #Bioanalysis #Barcelona2024

Due to pathogens developing antimicrobial resistance (AMR), it is pivotal that both healthcare professionals and the public become fully aware of how the development of AMR can best be avoided. Moreover, the occurrence of AMR underscores the urgent need for continued development of new anti-infective medicines to treat (severe) illness and prevent the risks of death and disease spread. Celerion is proud to have an extensive track record of clinical trials supporting the development of new antibiotics and other antimicrobial medicines. https://lnkd.in/eDK8sb73 #AMR #antimicrobial #clinicaltrials